ArticleMolecular cell2016
Drugging ACAT1 for Cancer Therapy.
Article in Molecular cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Targeting STARD4/EGFR axis inhibits growth and overcomes lenvatinib resistance in hepatocellular carcinoma.Genes & diseases · 2025Article
- RPL6 Interacts with HMGCS1 to Stabilize HIF-1α by Promoting Cholesterol Production in Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Target fishing and mechanistic insights of the natural anticancer drug candidate chlorogenic acid.Acta pharmaceutica Sinica. B · 2024Article
- Review
- Role of acetyl-CoA acetyltransferase 1 expression in the molecular mechanism of adenomyosis.Turkish journal of obstetrics and gynecology · 2023Article
- Article
- Lipid metabolism in pancreatic cancer: emerging roles and potential targets.Cancer communications (London, England) · 2022Review
- Identification and validation of transcription factor-driven enhancers of genes related to lipid metabolism in metastatic oral squamous cell carcinomas.BMC oral health · 2022Article
- Transcriptomic profiling of peroxisome-related genes reveals a novel prognostic signature in hepatocellular carcinoma.Genes & diseases · 2022Article
- Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel.Oncogene · 2021Article
- STARD4 promotes breast cancer cell malignancy.Oncology reports · 2020Article
- ACAT2 Promotes Cell Proliferation and Associates with Malignant Progression in Colorectal Cancer.OncoTargets and therapy · 2020Article
- Sex-specific hepatic lipid and bile acid metabolism alterations inThe Journal of biological chemistry · 2019Article
- Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs).Oncotarget · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue, Fan et al. (2016) show that oncogenic tyrosine kinases can promote glycolysis by phosphorylating and stabilizing the tetrameric form of mitochondrial acetyl-coA acetyltransferase 1 (ACAT1). The authors further identify a small molecule ACAT1 inhibitor that displays anti-cancer effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.